{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:06:31Z","timestamp":1756339591997,"version":"3.44.0"},"reference-count":36,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2022,12,11]]},"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:p>This case illustrates two diagnostic challenges for clinicians: the rarely described sixteen syndrome and the relationship between tumour necrosis factor (TNF)-alpha inhibitors and central demyelination. Sixteen syndrome affects horizontal eye movements and the facial nerve bilaterally reflecting a lesion in the posterior pontine tegmentum, adjacent to the fourth ventricle. Given its rarity and complexity of clinical signs, this syndrome risks misdiagnosis and mismanagement. The relationship between TNF-alpha inhibitors and demyelination is a complex issue in which causality is yet to be established. This diagnostic challenge poses a management dilemma for clinicians.<\/jats:p>","DOI":"10.1136\/bcr-2022-250440","type":"journal-article","created":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T10:06:22Z","timestamp":1673345182000},"page":"e250440","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Sixteen syndrome: a rare presentation of central demyelination"],"prefix":"10.1136","volume":"16","author":[{"given":"Francesca","family":"Bridge","sequence":"first","affiliation":[{"name":"Neurosciences, Monash University Faculty of Medicine Nursing and Health Sciences, Melbourne, Victoria, Australia"},{"name":"Neurology, Alfred Health, Melbourne, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Bennett","sequence":"additional","affiliation":[{"name":"Rheumatology, Box Hill Hospital, Box Hill, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Buzzard","sequence":"additional","affiliation":[{"name":"Neurology, Box Hill Hospital, Box Hill, Victoria, Australia"},{"name":"Neurosciences, Eastern Health, Monash University, Clayton, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,1,10]]},"reference":[{"key":"2025082711500561000_16.1.e250440.1","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419895155","article-title":"PPMS onset upon adalimumab treatment extends the spectrum of anti-TNF-\u03b1 therapy-associated demyelinating disorders","volume":"13","author":"Engel","year":"2020","journal-title":"Ther Adv Neurol Disord"},{"key":"2025082711500561000_16.1.e250440.2","doi-asserted-by":"crossref","DOI":"10.1007\/s11910-017-0742-1","article-title":"CNS demyelination with TNF-\u03b1 blockers","volume":"17","author":"Kemanetzoglou","year":"2017","journal-title":"Curr Neurol Neurosci Rep"},{"key":"2025082711500561000_16.1.e250440.3","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2009.11"},{"key":"2025082711500561000_16.1.e250440.4","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2020.1162","article-title":"Association between tumor necrosis factor inhibitor exposure and inflammatory central nervous system events","volume":"77","author":"Kunchok","year":"2020","journal-title":"JAMA Neurol"},{"key":"2025082711500561000_16.1.e250440.5","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1001\/jamainternmed.2015.5396","article-title":"Risk of demyelinating diseases in the central nervous system in patients with inflammatory bowel disease treated with tumor necrosis factor inhibitors","volume":"175","author":"Nyboe Andersen","year":"2015","journal-title":"JAMA Intern Med"},{"key":"2025082711500561000_16.1.e250440.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2013.09.002"},{"key":"2025082711500561000_16.1.e250440.7","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s10067-012-2002-8","article-title":"Rituximab in a patient with ankylosing spondylitis with demyelinating disease: a case report and review of the literature","volume":"31","author":"Omair","year":"2012","journal-title":"Clin Rheumatol"},{"key":"2025082711500561000_16.1.e250440.8","doi-asserted-by":"crossref","first-page":"691","DOI":"10.21037\/qims.2017.12.04","article-title":"One-and-a-half syndrome with its spectrum disorders","volume":"7","author":"Xue","year":"2017","journal-title":"Quant Imaging Med Surg"},{"key":"2025082711500561000_16.1.e250440.9","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.108217"},{"key":"2025082711500561000_16.1.e250440.10","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.108233"},{"key":"2025082711500561000_16.1.e250440.11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210770"},{"key":"2025082711500561000_16.1.e250440.12","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30470-2"},{"key":"2025082711500561000_16.1.e250440.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505066"},{"key":"2025082711500561000_16.1.e250440.14","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.70.2.252"},{"key":"2025082711500561000_16.1.e250440.15","unstructured":"Blumenfeld H . Neuroanatomy through clinical cases Sunderland. MA: Sinauer Associates, Inc, 2002."},{"key":"2025082711500561000_16.1.e250440.16","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/00041327-200503000-00015","article-title":"One-and-a-half syndrome with facial diplegia: the 15 1\/2 syndrome?","volume":"25","author":"Bae","year":"2005","journal-title":"J Neuroophthalmol"},{"key":"2025082711500561000_16.1.e250440.17","doi-asserted-by":"crossref","unstructured":"Jens W , Ahmed A . Eight and a half syndrome from multiple sclerosis. J neurol stroke 2015;3.doi:10.15406\/jnsk.2015.02.00099","DOI":"10.15406\/jnsk.2015.03.00099"},{"key":"2025082711500561000_16.1.e250440.18","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/WNO.0b013e318284240d","article-title":"16 syndrome in a patient with multiple sclerosis","volume":"33","author":"Lee","year":"2013","journal-title":"J Neuroophthalmol"},{"key":"2025082711500561000_16.1.e250440.19","first-page":"69","article-title":"One-and-a-half syndrome with facial diplegia: a case report","volume":"22","author":"Sun","year":"2017","journal-title":"Neurology Asia"},{"key":"2025082711500561000_16.1.e250440.20","doi-asserted-by":"crossref","first-page":"omx085","DOI":"10.1093\/omcr\/omx085","article-title":"Case report of a patient with 'one-and-a-half plus syndrome: nine syndrome'","volume":"2018","author":"Uthman","year":"2018","journal-title":"Oxf Med Case Reports"},{"key":"2025082711500561000_16.1.e250440.21","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.55.10.863"},{"key":"2025082711500561000_16.1.e250440.22","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2017.00611","article-title":"Isolated horizontal gaze palsy: observations and explanations","volume":"8","author":"Ewe","year":"2017","journal-title":"Front Neurol"},{"key":"2025082711500561000_16.1.e250440.23","doi-asserted-by":"crossref","first-page":"51iii","DOI":"10.1136\/ard.61.suppl_3.iii51","article-title":"Anti-tumour necrosis factor alpha therapy for ankylosing spondylitis: international experience","volume":"61 Suppl 3","author":"Braun","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"2025082711500561000_16.1.e250440.24","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W"},{"key":"2025082711500561000_16.1.e250440.25","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577587","article-title":"CNS demyelination with TNF\u03b1 inhibitor exposure: a retrospective cohort study","volume":"356","author":"Hutto","year":"2021","journal-title":"J Neuroimmunol"},{"key":"2025082711500561000_16.1.e250440.26","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1007\/s00415-021-10460-6","article-title":"Clinical course of central nervous system demyelinating neurological adverse events associated with anti-TNF therapy","volume":"268","author":"Cortese","year":"2021","journal-title":"J Neurol"},{"key":"2025082711500561000_16.1.e250440.27","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.47.6.1531"},{"key":"2025082711500561000_16.1.e250440.28","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.53.3.457"},{"key":"2025082711500561000_16.1.e250440.29","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200109)44:9<1977::AID-ART345>3.0.CO;2-6"},{"key":"2025082711500561000_16.1.e250440.30","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2006.00779.x"},{"key":"2025082711500561000_16.1.e250440.31","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.043166"},{"key":"2025082711500561000_16.1.e250440.32","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1002\/art.10488","article-title":"Successful rechallenge with anti-tumor necrosis factor alpha for psoriatic arthritis after development of demyelinating nervous system disease during initial treatment: comment on the article by Mohan et al","volume":"46","author":"Cisternas","year":"2002","journal-title":"Arthritis Rheum"},{"key":"2025082711500561000_16.1.e250440.33","doi-asserted-by":"crossref","first-page":"143","DOI":"10.12659\/AJCR.900563","article-title":"Rituximab can induce remission in a patient with ankylosing spondylitis who failed anti-TNF-\u03b1 agent","volume":"18","author":"AlDhaheri","year":"2017","journal-title":"Am J Case Rep"},{"key":"2025082711500561000_16.1.e250440.34","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci11010038","article-title":"The role of non-selective TNF inhibitors in demyelinating events","volume":"11","author":"Kristensen","year":"2021","journal-title":"Brain Sci"},{"key":"2025082711500561000_16.1.e250440.35","first-page":"1","article-title":"Demyelinating disease following Anti-TNFa treatment: a causal or coincidental association? report of four cases and review of the literature","volume":"2013","author":"Andreadou","year":"2013","journal-title":"Case Rep Neurol Med"},{"key":"2025082711500561000_16.1.e250440.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2010.06.004"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2022-250440","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T18:50:16Z","timestamp":1756320616000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2022-250440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1,10]]},"published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1136\/bcr-2022-250440"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2022-250440","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2023,1]]}}}